- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01534364
Brief Title:Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery (CR_KCH)
Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery
Study Overview
Detailed Description
Patients with cardiothoracic surgery are at risk for postoperative acute renal failure which is associated with significant morbidity and mortality. There is no drug or procedure known to prevent this loss of renal function. Experimental data suggests, that a preoperative caloric restriction might provide kidney protection in this context. This clinical trial investigates if this phenomenon is also applicable in humans. Patients with a increased risk for a postoperative renal failure due to known chronic kidney disease are randomized in 2 groups. Patients of the diet group receive a calorie restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery). Patients of the control group receive alimentation ad libitum.
Primary objective is the increase of serum creatinine in mg/dl 24 h after induction of ischemia ("cross clamping") in comparison to baseline value obtained in the morning of the day of surgery (day 0) in order to analyse if a preoperative calorie restriction as a preventive strategy leads to a attenuation of postoperative kidney injury. Hypothesis: A seven day calorie restriction reduces the increase of serum creatinine after cardiac surgery in patients with known chronic kidney disease.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Cologne, Germany, 50937
- University of Cologne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women 18 years of age or older
- Caucasian origin
- Scheduled cardiothoracic operation with employment of cardio-pulmonary bypass and a lead time of 11 days minimum.
- Indication for cardiac surgery is determined by the cardiothoracic specialist
- Patient and/or legal guardian must be willing and able to give written informed consent
one of the following risk factors:
- serum creatinine >1,1 mg/dl in male and > 0,9 mg/dl in female
- type 2 diabetes
- peripheral artery occlusive disease
- heart failure with NYHA III-IV (ejection fraction < 50 %)
- combined CABG and heart valve surgery
- further surgery after CABG or heart valve surgery
Exclusion Criteria:
- End-stage renal disease (patient on dialysis)
- Indwelling kidney transplant
- Malnutrition (BMI < 18,5 kg/m2)
- Body weight < 46 kg in male and < 51 kg in female
- BMI > 35 kg/m2 or body weight > 120 kg
- Catabolic state (serum albumine < 25 g/l)
- Diet within the previous 4 weeks
- Inappetence
- Weight loss > 1 kg within the previous 2 weeks, if not explained by use of diuretics
- Hospital stay during the last 7 days prior to cardiac surgery
- Consuming underlying disease
- Uncontrolled local or systemic infection
- Contraindication for enteral nutrition.
- Known allergy against or incompatibility with ingredients of the employed formula-diet
- Pregnancy or breast feeding
- Participation in other interventional clinical trials.
- Missing safe method of contraception or missing occurence of menopause (in female)
- Professional or private relationship between subject and the investigators or dependence on the investigators.
- Placement in an institution based on official orders.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: control
Ad libitum alimentation
|
|
|
Other: calorie restriction
Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery day 0 corresponds to day of surgery)
|
Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The Increase of serum creatinine in mg/dl 24 h after induction of ischemia ("cross clamping") in comparison to baseline value obtained in the morning of the day of surgery (day 0).
Time Frame: baseline and 24 hours after induction of ischemia
|
baseline and 24 hours after induction of ischemia
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Urine Neutrophil-Gelatinase associated Lipocalin (NGAL in µg/l) 8h after induction of ischemia in comparison to baseline value obtained in the morning of the day of surgery (day 0).
Time Frame: baseline and 8 hours after induction of ischemia
|
baseline and 8 hours after induction of ischemia
|
|
C-reactive Protein (CRP) 24h after induction of ischemia
Time Frame: baseline and 24 h after induction of ischemia
|
baseline and 24 h after induction of ischemia
|
|
Leucocyte count 24h after induction of ischemia
Time Frame: baseline and 24h after induction of ischemia
|
baseline and 24h after induction of ischemia
|
|
Creatinkinase (CK) 24h after induction of ischemia
Time Frame: baseline and 24 h after induction of ischemia
|
baseline and 24 h after induction of ischemia
|
|
Troponin T 24h after induction of ischemia
Time Frame: baseline and 24 h after induction of ischemia
|
baseline and 24 h after induction of ischemia
|
|
Lactate dehydrogenase 24h after induction of ischemia
Time Frame: baseline and 24 h after ischemia
|
baseline and 24 h after ischemia
|
|
N-terminal pro brain natriuretic peptide (NT-ProBNP) 24h after induction of ischemia
Time Frame: baseline and 24 h after ischemia
|
baseline and 24 h after ischemia
|
|
Serum lactate 24h after induction of ischemia
Time Frame: baseline and 24 hours after ischemia
|
baseline and 24 hours after ischemia
|
|
Maximum increase of serum creatinine within the first 48 h after induction of ischemia
Time Frame: baseline and 48 hours after ischemia
|
baseline and 48 hours after ischemia
|
|
Necessity of renal replacement therapy during hospital stay
Time Frame: pt will be followed for the duration of hospital stay, an expected average of 10 days
|
pt will be followed for the duration of hospital stay, an expected average of 10 days
|
|
In-hospital mortality
Time Frame: pt will be followed for the duration of hospital stay, an expected average of 10 days
|
pt will be followed for the duration of hospital stay, an expected average of 10 days
|
|
Time until fit for discharge
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 10 days
|
Participants will be followed for the duration of hospital stay, an expected average of 10 days
|
|
Length of hospital stay
Time Frame: Pt will be followed for the duration of hospital stay an expected average of 10 days
|
Pt will be followed for the duration of hospital stay an expected average of 10 days
|
|
Echocardiographic estimated left-ventricular ejection fraction as per file, if assessed postoperatively
Time Frame: baseline and postoperatively, expected within 10 days after operation
|
baseline and postoperatively, expected within 10 days after operation
|
|
Occurrence of acute renal failure in accordance with KDIGO I, II, III
Time Frame: Patients will be followed during hospital stay, an expected average of 10 days
|
Patients will be followed during hospital stay, an expected average of 10 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Volker Burst, MD, University of Cologne
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 001 (Buy Pharma Ecza Deposu San. Tic. Ltd.)
- 00003355 (Registry Identifier: DRKS)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Renal Failure
-
Wake Forest University Health SciencesCompletedRenal Replacement Therapy | Kidney Failure, AcuteUnited States
-
University Hospital, Clermont-FerrandRecruitingAcute Kidney Injury | Transient Acute Renal Failure | Persistent Acute Renal FailureFrance
-
University Hospital, GhentCompletedAcute Renal Failure | Chronic Renal FailureBelgium
-
Washington University School of MedicineCompletedAcute Renal Failure | Chronic Renal FailureUnited States
-
University Hospital, GrenobleRecruitingRenal Insufficiency | Renal Failure | Acute Renal Failure | Acute Renal InsufficiencyFrance
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
InCor Heart InstituteUnknownAcute Kidney Injury | Acute Renal Failure | Acute Renal InjuryBrazil, Spain
-
RenaMed BiologicsTerminatedKidney Failure, AcuteUnited States
-
University of AlbertaAlberta Heritage Foundation for Medical ResearchCompletedAcute Renal Failure | Chronic Renal Failure | Contrast-induced NephropathyCanada
-
Medical University of GdanskTerminatedAcute Renal FailurePoland
Clinical Trials on calorie restriction
-
University of South CarolinaCompleted
-
St. Louis UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of AarhusUniversity of Southern Denmark; University GhentCompletedOverweight and ObesityDenmark
-
SINEM BAYRAMCompletedObesity and Metabolic SyndromeTurkey
-
University of PernambucoUniversidade Federal de PernambucoEnrolling by invitationSarcopenia | Cardiac Disease | Metabolic Disease | Abdominal Obesity | Cardiometabolic SyndromeBrazil
-
Washington University School of MedicineCompleted
-
University of California, San FranciscoNational Institutes of Health (NIH)CompletedModerately Overweight IndividualsUnited States
-
Chin HsuCompleted
-
Brigham and Women's HospitalCompleted